Iterion Therapeutics
- Website
- iteriontherapeutics.com
- Total Funding
- $24.1M
- Last Round
- $7.1M GrantNov 2025
- Rounds
- 2
About
Iterion Therapeutics is developing tegavivint, a novel small-molecule inhibitor that binds to TBL1 and disrupts the interaction between beta-catenin and TBL1, promoting degradation of nuclear beta-catenin and preventing transcription of Wnt/beta-catenin targeted oncogenes. Preclinical studies have shown tegavivint inhibits beta-catenin activity without overt toxicity and is not affected by CTNNB1 gain-of-function mutations typically found in cancer cells. In parallel with the tegavivint program, Iterion has ongoing R&D programs investigating and developing second-generation TBL1 inhibitors.
Summary
Iterion Therapeutics is a Biotech company. It has raised $24.1M in total across 2 rounds, most recently a $7.1M Grant round in Nov 2025. Investors include Cancer Prevention and Research Institute of Texas, Sante Ventures and Lumira Ventures.
Funding History
Nov 2025
Sign up to see all 2 rounds
Series B through Grant — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Specialty pharmaceutical company focused on addressing therapeutic needs in the fields of psychia...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/iterion-therapeutics"><img src="https://indexed.vc/api/badge/company/iterion-therapeutics" alt="Iterion Therapeutics on Indexed.vc" width="260" height="76" /></a>